NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Item

http://www.wikidata.org/entity/Q39294181

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@en

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@nl

type

Item

label

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@en

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@nl

prefLabel

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@en

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@nl

P1476

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

@en

P2093

Daniel Sommermeyer

http://www.w3.org/2001/XMLSchema#string

Haike Gelfort

http://www.w3.org/2001/XMLSchema#string

Heinke Conrad

http://www.w3.org/2001/XMLSchema#string

Helga Bernhard

http://www.w3.org/2001/XMLSchema#string

Holger Krönig

http://www.w3.org/2001/XMLSchema#string

Wolfgang Uckert

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Immunotherapy with CTLs restricted by nonself MHC.

Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death.

LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

NY-ESO-1: review of an immunogenic tumor antigen.

Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells

P304

1360-1367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.27792

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230711845

http://www.w3.org/2001/XMLSchema#string

P698

22907642

http://www.w3.org/2001/XMLSchema#string

P932

3617456

http://www.w3.org/2001/XMLSchema#string